Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-21

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Pevonedistat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda's blood cancer drug flunks phase 3 in setback to R&D pla
    Takeda's blood cancer drug flunks phase 3 in setback to R&D pla

    03 Sep 2021

    // N. P Taylor FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/not-waving-but-drowning-takeda-s-blood-cancer-drug-flunks-phase-3-dealing-further-blow-to

    N. P Taylor FIERCEBIOTECH
    03 Sep 2021
    Share Share
    Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
    Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

    01 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210901005908/en

    BUSINESSWIRE
    01 Sep 2021
    Share Share
    Takeda Announces U.S. FDA Breakthrough Therapy Granted for Pevonedistat
    Takeda Announces U.S. FDA Breakthrough Therapy Granted for Pevonedistat

    30 Jul 2020

    // PRESS RELEASE

    https://www.takeda.com/newsroom/newsreleases/2020/takeda-announces-u.s.-fda-breakthrough-therapy-designation-granted-for-pevonedistat-for-the-treatment-of-patients-with-higher-risk-myelodysplastic-syndromes-hr-mds/

    PRESS RELEASE
    30 Jul 2020
    Share Share